Tongfei Wu

USPTO Granted Patents = 27 (Patent Applications = 6)

CIPO Patents = 1

EPO Patents = 10 (Patent Applications = 13)

Average Co-Inventor Count = 7.1

ph-index = 3

Forward Citations = 47(Granted Patents)

Location History:

Turnhout, BE (2014 - 2015)
Leuven, BE (2011 - 2016)
Jette, BE (2015 - 2020)
Boortmeerbeek, BE (2021 - 2024)
Hever, BE (2021 - 2024)

Company Filing History:

16 out of 2,076

Janssen Pharmaceutica Nv

patents

5 out of 84

K.u. Leuven Research & Development

patents

4 out of 34

Aligos Therapeutics, Inc.

patents

4. 2 out of 159

Janssen Pharmaceuticals, Inc.

where one patent can have more than one assignee

Years Active: 2011-2025

Loading Chart...

27 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12428427 - Methods and compositions for targeting PD-L1 (2025-09-30),

2. 12404260 - Pyridine rings containing derivatives as MALT1 inhibitors (2025-09-02),

3. 12145961 - Spirobicyclic analogues (2024-11-19),

4. 12077521 - Pyrazole derivatives as MALT1 inhibitors (2024-09-03),

5. 12018015 - Methods and compositions for targeting PD-L1 (2024-06-25),

6. 11993614 - Monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as PRMT5 inhibitors (2024-05-28),

7. 11883367 - 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as PRMT5 inhibitors (2024-01-30),

8. 11760764 - Methods and compositions for targeting PD-L1 (2023-09-19),

9. 11760761 - Methods and compositions for targeting PD-L1 (2023-09-19),

10. 11702441 - Spirobicyclic analogues (2023-07-18),

11. 11571437 - Methods of treating cancer using PRMT5 inhibitors (2023-02-07),

12. 11318157 - 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as PRMT5 inhibitors (2022-05-03),

13. 11098062 - Monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as PRMT5 inhibitors (2021-08-24),

14. 11059850 - Spirobicyclic analogues (2021-07-13),

15. 11040031 - Pyrazole derivatives as MALT1 inhibitors (2021-06-22),

Title: Tongfei Wu: Innovator in Pharmaceutical Compounds

Introduction

Tongfei Wu, based in Hever, Belgium, is an accomplished inventor with a remarkable portfolio of 20 patents. His work primarily focuses on the development of novel pharmaceutical compounds that target various biological pathways. Wu's innovative contributions to the field have the potential to impact the treatment of several diseases.

Latest Patents

Among his most recent patents are the following notable inventions:

1. **Spirobicyclic Analogues** - This invention relates to novel spirobicyclic analogues of Formula (I), designed to function as PRMT5 inhibitors. The compounds offer valuable pharmaceutical applications, further elucidated by their formulations and potential use as medicaments.

2. **Pyrazole Derivatives as MALT1 Inhibitors** - This patent discloses various compounds, compositions, and methods aimed at treating conditions influenced by MALT1 modulation. The detailed structure represented by Formula (I) highlights the versatile applications of these compounds.

Career Highlights

Tongfei Wu has worked with prominent companies in the pharmaceutical industry, including Janssen Pharmaceutica and Aligos Therapeutics, Inc. His experience in these organizations has equipped him with essential knowledge and skills crucial for successful invention in the pharmaceutical domain.

Collaborations

During his career, Wu has collaborated with esteemed colleagues such as Lieven Meerpoel and Johannes Wilhelmus John F Thuring. This partnership has allowed for the melding of ideas and expertise, further advancing the development of innovative therapeutics.

Conclusion

Tongfei Wu is a significant contributor to the field of pharmaceuticals, with a robust collection of patents that demonstrate his dedication to innovation. His groundbreaking work on spirobicyclic analogues and pyrazole derivatives underscores the potential for innovative treatments that may revolutionize patient care. Wu's endeavors will undoubtedly inspire future research and development in medical science.

This text is generated by artificial intelligence and may not be accurate.